AAP News Vol. 13 No. 5 May 1997, p. 23
© 1997 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

 Previous Article  |  Next Article 

Children's Luvox approved

Luvox (Fluvoxamine maleate) is the first selective serotonin reuptake inhibitor (SSRI) to gain U.S. Food and Drug Administration clearance for the treatment of obsessive compulsive disorder (OCD) in children and adolescents.

Characterized by excessive fear, anxiety, doubt and fixations, OCD is experienced by close to one million U.S. children. According to a company spokesperson, three to five children within the average elementary classroom are plagued by OCD, believed to be caused by a chemical imbalance in the brain.